Forest Keeps Up Lexapro Detailing Pressure In Face Of Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest's antidepressant continues to be the most detailed product in the class, the company says; aggressive detailing is increasingly important with Forest's loss of exclusivity for Celexa and Lilly's launch of Cymbalta. Forest expects Lexapro to be approved for social anxiety and panic disorders early this year.
You may also be interested in...
Forest Expects Lexapro To Gain Share In Flat Antidepressant Market
The company projects escitalopram total Rx share will increase from 19.7% to 21.5% in the next 12 months while the antidepressant market will be down 0.5% for the same period. Lexapro market share has seen a "modest boost" as a result of FDA's seizure of GSK's Paxil CR.
Forest Expects Lexapro To Gain Share In Flat Antidepressant Market
The company projects escitalopram total Rx share will increase from 19.7% to 21.5% in the next 12 months while the antidepressant market will be down 0.5% for the same period. Lexapro market share has seen a "modest boost" as a result of FDA's seizure of GSK's Paxil CR.
Forest Takes "Wait And See" Approach On Effect Of Antidepressant "Black Box" Labeling
The company does not anticipate a "dramatic disruption" to the marketplace since the safety issues have been widely publicized, COO Goodman says. He suggests that the effect on Lexapro sales could mirror the temporary dip seen when the safety issues first surfaced last summer.